Johnson & Johnson To Settle New Hampshire Opioid Lawsuit With Payment Of $40.5M: Report
Reuters reported that Johnson & Johnson (NYSE:JNJ) would pay $40.5 million to settle 2018 New Hampshire’s claims about the U.S. opioid epidemic,…
PolyPid’s Lead Program Flunks Abdominal Surgery Study, Shares Tank
PolyPid Ltd (NASDAQ: PYPD) shares lost almost 80% after announcing topline results from the SHIELD I Phase 3 study of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal surgery.
Immuneering Shares Climb After Pursuing FDA Nod For RAS Mutant Tumor Study
Immuneering (NASDAQ: IMRX) submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its product candidate IMM-1-104 in development for the treatment of advanced RAS mutant solid tumors.
PolyPid Announces Top-line Results Of Phase 3 SHIELD I Trial Of D-PLEX100 Did Not Achieve Its Primary Endpoint For The Prevention Of Surgical Site Infections In Abdominal Surgery
SHIELD I Study did not Achieve its Primary Endpoint of Reduction in Surgical Site Infections and Mortality
In an FDA Requested Pre-specified Subgroup Analysis in Subjects with Incision Lengths over 20 centimeters
Microbot Medical Confirms GLP Pre-Clinical Trial Is On Track To Commence Later This Month
HINGHAM, Mass., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT) announced, as part of the preparation for its anticipated U.S. Food and Drug Administration (FDA) and CE Mark submissions, that it
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002,…
FDA Advisory Committee Meeting Scheduled For October 28, 2022 To Review Y-mAbs’ Refiling For Omburtamab
The Oncologic Drugs Advisory Committee (ODAC) of the U.S.
Intellia Gets FDA Orphan Drug Status For Hereditary Angioedema Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ: NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE).
NTLA-2002 is currently being evaluated in a Phase 1/2 study in adults with Type I or Type II HAE.
Europe Backs Approval Of Omicron-Adapted COVID-19 Vaccines
Health Canada has approved Moderna Inc's (NASDAQ: